NCT07429708 Ropivacaine Hydrochloride Pain Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07429708 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.

MCP evidence snapshot: 24 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.

Why NCT07429708 is a hot trial to watch

Pain is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07429708 is notable because it evaluates Ropivacaine Hydrochloride in a Phase 3 design sponsored by Universitas Udayana. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.

Trial landscape snapshot

Protocol design and endpoint interpretation

Laminectomy is a routine procedure for patients with lumbar spinal stenosis, offering significant benefits such as reduced low back pain, alleviation of radiculopathy, and improved motor strength 1 23. Despite these advantages, postoperative pain remains a challenge for anesthesiologists. According to Davin et al., approximately 80% of patients undergoing lumbar laminectomy experience postoperative discomfort, with 20% developing persistent postsurgical pain (PPSP). The application of erector spinae plane (ESP) block in lumbar laminectomy surgery significantly reduces postoperative pain and hospital length of stay. However, ESP block without adjuvants has limitations in duration. Adjuvants are thus required to optimize the effects of ESP block 4. Dexamethasone is a glucocorticoid that is widely used in the perioperative setting. Interfascial administration of dexamethasone has been shown to prolong the duration of analgesia provided by

Allocation is Randomized, masking is Double, and the intervention model is Parallel Assignment. Planned enrollment of [object Object] participants across Indonesia shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.

• Duration of Analgesia (From the completion of the ESP block until the first request for rescue analgesia (assessed up to 24 hours post-surgery)) — This represents the duration of analgesia, defined as the time from the administration of the Erector Spinae Plane (ESP) block until the patient first presses the Patient-Controlled Analgesia (PCA) fentanyl button. The data is presented in minutes.
• Postoperative increase in PGE2 levels (PGE2 Levels Preoperatively (baseline) and 24 hours after surgery) — The mean baseline prostaglandin E2 (PGE2) level was significantly lower in the dexamethasone group than in the non-adjuvant group (9.36 ± 2.57 vs 12.72 ± 4.35 ng/L; p = 0.008). The median postoperative increase in PGE2 was also significantly smaller in the dexamethasone group compared with the control group (7.03 \[IQR 13.79\] vs 19.05 \[IQR 34.56\]; p = 0.016)
• Postoperative VAS pain scores at 8, 12, 16, and 24 hours (8, 12, 16, and 24 hours after the surgery done) — Postoperative Visual Analogue Scale (VAS) is a pain assessment score widely used in research and clinical practice to evaluate the intensity of subjective experiences, such as pain or discomfort, consisting of a 100 mm line with descriptive anchors. Assessments were performed at 8, 12, 16, and 24 hours postoperatively. Numerical variables are presented as mean and standard deviation (SD) for normally distributed data
• Postoperative PCA Fentanyl requirements (8, 12, 16, and 24 hours after surgery) — Postoperative fentanyl PCA requirements. These represent the postoperative fentanyl requirements at 8, 12, 16, and 24 hours, as recorded by the Patient-Controlled Analgesia (PCA) pump, starting from the Post-Anesthesia Care Unit (PACU) up to 24 hours postoperatively. Numerical variables are presented as mean and standard deviation (SD) for normally distributed data, or as median and interquartile range (IQR) for non-

Readout outlook and evidence gap

The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.

Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset MCP profile: Ropivacaine Hydrochloride is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.

Company & Deal Intelligence MCP profile: Universitas Udayana is resolved to a normalized organization record in Indonesia. The organization workflow adds identity, location, portfolio and partnering context where available.

The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

• Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
• Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
• Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
• Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
• Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.

What to monitor next

Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.

Bottom line

NCT07429708 provides a focused lens on Pain development. Its value will be determined by whether Ropivacaine Hydrochloride can convert the current Phase 3 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.